Long-term safety of solriamfetol for ADHD in children and teens
Treatments studied
Part of Mental health clinical trials.
This study checks the long-term safety of the drug solriamfetol for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents who have already completed an earlier study of this medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed either the FOCUS-2 or FOCUS-3 study of solriamfetol for ADHD.
- A parent or legal guardian must be able to give written permission, and you must be willing to agree (assent) to take part.
- You must be able to follow the study's rules and procedures.
- The study doctor must decide that it is safe and appropriate for you to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medication called solriamfetol can safely help children with ADHD. If your child is between 6 and 12 years old and has ADHD, this study may be an option.
This study tests a new medicine, solriamfetol, to see if it helps teenagers with ADHD. The medicine is taken as a tablet and may improve focus and reduce symptoms.
This study looks at how ADHD medications and small head movements during brain scans affect attention. It may help researchers understand how these medicines work, which could improve ADHD care.
This study tests a medication called Solriamfetol (Sunosi) to see if it helps people with shift work disorder stay awake and alert during their shifts. It is a Phase 3 trial, which means it is being studied in a larger group to confirm how well it works and check for side effects.
This study checks how safe a kid’s ongoing treatment is over a longer period. It is mainly for children who already finished a related study and may benefit from continuing the same medicines.
This study looks at the long-term safety and effectiveness of the medication solriamfetol for people with binge eating disorder. If you were in the earlier SOL-BED-301 study, this gives you a chance to continue treatment and see how it works over a longer time.
Hear when a new ADHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.